期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
不同世界卫生组织胸腺瘤组织学分类和Masaoka-Koga分期胸腺瘤患者的临床病理特征差异分析
1
作者 董晓英 《中外医药研究》 2024年第6期18-20,共3页
目的:分析不同世界卫生组织胸腺瘤组织学分类(简称WHO分型)和Masaoka-Koga分期胸腺瘤患者的临床病理特征差异。方法:回顾性分析2012年3月—2023年12月于贺州市人民医院行手术治疗的48例胸腺瘤患者的病历资料。比较不同WHO分型和Masaoka-... 目的:分析不同世界卫生组织胸腺瘤组织学分类(简称WHO分型)和Masaoka-Koga分期胸腺瘤患者的临床病理特征差异。方法:回顾性分析2012年3月—2023年12月于贺州市人民医院行手术治疗的48例胸腺瘤患者的病历资料。比较不同WHO分型和Masaoka-Koga分期胸腺瘤患者临床特征的差异,采用Spearman相关系数分析其相关性。结果:48例胸腺瘤患者中良性12例,恶性36例,其中A型3例,AB型9例,B1型12例,B2型15例,B3型5例,B2-B3混合型4例。不同WHO分型患者年龄、性别、症状发生率、发病部位、肿瘤直径比较,差异无统计学意义(P>0.05);恶性患者Ki-67≤10%占比大于良性患者,差异有统计学意义(P=0.040)。48例胸腺瘤患者中早期35例,晚期13例,其中Ⅰ期7例,Ⅱ期28例,Ⅲ期7例,Ⅳ期6例。不同Masaoka-Koga分期患者年龄、性别、症状发生率、发病部位、Ki-67水平比较,差异无统计学意义(P>0.05);晚期患者肿瘤直径>8 cm占比大于早期患者,差异有统计学意义(P=0.020)。Spearman相关分析显示,胸腺瘤患者Masaoka-Koga分期与肿瘤直径呈正相关(r=0.337,P=0.019),WHO分型与Masaoka分期呈正相关(r=0.407,P=0.004)。结论:胸腺瘤患者Masaoka-Koga分期与肿瘤直径、WHO分型均呈正相关,可通过以上参数评估胸腺瘤恶性程度,为临床治疗胸腺瘤提供参考。 展开更多
关键词 胸腺瘤 世界卫生组织胸腺瘤组织学分类 masaoka-koga分期
下载PDF
基于CT图像纹理分析预测胸腺上皮性肿瘤Masaoka-Koga分期的研究 被引量:4
2
作者 辛永康 施耀军 +2 位作者 胡玉川 崔光彬 贺延莉 《影像诊断与介入放射学》 2023年第3期163-168,共6页
目的探讨CT图像纹理分析在预测胸腺上皮性肿瘤(TETs)Masaoka-Koga分期中的价值。方法回顾性分析经手术病理证实的114例TETs患者的CT图像,根据Masaoka-Koga分期将TETs分为早期(Ⅰ~Ⅱ期)与进展期(Ⅲ~Ⅳ期)。提取CT平扫及增强图像上肿瘤各... 目的探讨CT图像纹理分析在预测胸腺上皮性肿瘤(TETs)Masaoka-Koga分期中的价值。方法回顾性分析经手术病理证实的114例TETs患者的CT图像,根据Masaoka-Koga分期将TETs分为早期(Ⅰ~Ⅱ期)与进展期(Ⅲ~Ⅳ期)。提取CT平扫及增强图像上肿瘤各期的纹理参数,对纹理参数进行降维后求得加权Rad-score值,使用受试者工作特征(ROC)曲线分析纹理特征的预测效能。结果114例TETs患者中包括男58例,女56例;早期61例,进展期53例。基于CT图像纹理分析,在鉴别早期和进展期TETs时CT平扫参数V_(14)(Kurtosis)、V_(462)(Correlation_angle90_offset9)、V_(481)(Sum Entropy)等参数具有统计学意义(均P<0.05),动脉期V_(16)(Histogram Energy)、V_(32)(Percentile70)、V_(481)(Sum Entropy)等参数具有统计学意义(均P<0.05);静脉期V_(148)(GLCM Entropy_offset3_SD)、V_(469)(Inertia_angle135_offset9)、V_(966)(LRE_offset9)等参数具有统计学意义(均P<0.001);Rad-score值在鉴别早期和进展期TETs方面:CT平扫、动脉期和静脉期的AUC值分别为0.692(0.595,0.789)、0.878(0.813,0.944)和0.685(0.603,0.767)。结论CT图像纹理分析在术前预测TETs的Masaoka-Koga分期中具有潜在价值,有助于对TETs患者进行个性化诊疗。 展开更多
关键词 胸腺上皮性肿瘤 体层摄影术 X线计算机 纹理分析 masaoka-koga分期
下载PDF
胸腺上皮性肿瘤体积与WHO分型及Masaoka-Koga分期的相关性研究 被引量:2
3
作者 宋佳 张砚满 吴献华 《交通医学》 2022年第3期281-283,共3页
目的:探讨胸腺上皮性肿瘤(thymic epithelial tumors,TETs)体积与WHO分型及Masaoka-Koga临床分期的相关性。方法:术后病理证实为TETs患者125例,2015年WHO分型:A型7例,AB型32例,B1型20例,B2型34例,B3型12例,胸腺癌20例;简化分组:低危型... 目的:探讨胸腺上皮性肿瘤(thymic epithelial tumors,TETs)体积与WHO分型及Masaoka-Koga临床分期的相关性。方法:术后病理证实为TETs患者125例,2015年WHO分型:A型7例,AB型32例,B1型20例,B2型34例,B3型12例,胸腺癌20例;简化分组:低危型胸腺瘤(A、AB、B1型)59例,高危型胸腺瘤(B2、B3型)46例和胸腺癌20例;Masaoka-Koga分期:I期45例,Ⅱ期50例,Ⅲ期12例,Ⅳ期18例,其中I期为非侵袭性TETs,Ⅱ-Ⅳ期为侵袭性TETs。分析TETs肿瘤体积与WHO组织分型及Masaoka-Koga临床分期的相关性,采用ROC曲线分析肿瘤体积预测侵袭性TETs的临界值及其效能。结果:WHO各分型肿瘤体积比较,差异均无统计学意义(P>0.05)。MasaokaKoga分期I期与Ⅲ期,I期与Ⅳ期,Ⅱ期与Ⅳ期,Ⅲ期与Ⅳ期肿瘤体积比较,差异均有统计学意义(P<0.05)。侵袭性TETs肿瘤体积明显大于非侵袭性TETs,差异有统计学意义(P<0.05)。ROC曲线分析显示肿瘤体积预测侵袭性TETs的临界值为51.4 cm3,敏感度为88.9%,特异度为62.5%。结论:TETs肿瘤体积与Masaoka-Koga分期具有一定相关性,肿瘤过大提示侵袭性TETs。 展开更多
关键词 胸腺上皮性肿瘤 肿瘤体积 侵袭性 WHO分型 masaoka-koga分期
下载PDF
Thymoma: current diagnosis and treatment 被引量:40
4
作者 Frank C. Detterbeck Ahmad Zeeshan 《Chinese Medical Journal》 SCIE CAS CSCD 2013年第11期2186-2191,共6页
Objective To review the presentation, diagnosis, staging and treatment of thymoma. Data sources Data were obtained from papers on thymoma published in English within the last 30 years. No formal systematic review was ... Objective To review the presentation, diagnosis, staging and treatment of thymoma. Data sources Data were obtained from papers on thymoma published in English within the last 30 years. No formal systematic review was conducted, but an effort was made to be comprehensive. Study selection Studies were selected if they contained data relevant to the topic addressed in the particular section. In particular, standards adopted by the International Thymic Malignancies Interest Group through a formal process of achieving worldwide consensus are featured. Because of the limited length of this article, we have frequently referenced recent reviews that contain a comprehensive amalgamation of literature rather than the actual source papers. Results Thymomas are rare malignant tumors. They account for about half (47%) of anterior mediastinal tumors. About one third of these are associated with myasthenia gravis. Computed tomography with intravenous contrast is the standard diagnostic modality. Thymomas appear as round or oval masses in early stages but irregular shapes with calcifications occurring in later stages. They can invade surrounding structures including mediastinal fat, pleura, major blood vessels and nerves. Fine needle aspiration, core needle biopsy or open biopsy is used to obtain tissue diagnosis. Masaoka-Koga classification is currently used to stage thymomas. All thymomas should be considered for resection due to their malignant potential. A complete resection is a major prognostic factor and every effort should be made to achieve this even if this means resection and reconstruction of a major thoracic structure. Median sternotomy is the standard approach for thymoma resection. A number of minimally invasive techniques are used in selective centers. While stage I and II tumors undergo primary surgery, preoperative chemotherapy appears to increase the chances of complete resection for stage III and IVa tumors. Postoperative radiation could be considered for patients with residual disease. Excellent 5 and 10-year survival rates are noted for completely resected early stage thymomas. Conclusions Thymic malignancies are rare tumors. Standards have recently been achieved to allow better communication and promote collaborative research. Surgical resection is the mainstay of treatment, but a multimodality approach is useful for many patients. 展开更多
关键词 THYMOMA myasthenia gravis MEDIASTINUM masaoka-koga classification
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部